<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v3.0 20080202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing3.dtd?><?SourceDTD.Version 3.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Acta Naturae</journal-id><journal-id journal-id-type="iso-abbrev">Acta Naturae</journal-id><journal-id journal-id-type="publisher-id">ActaNaturae</journal-id><journal-title-group><journal-title>Acta Naturae</journal-title></journal-title-group><issn pub-type="ppub">2075-8251</issn><publisher><publisher-name>A.I. Gordeyev</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7245956</article-id><article-id pub-id-type="doi">10.32607/actanaturae.10935</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject><subj-group><subject>Molecular Biology</subject></subj-group></subj-group></article-categories><title-group><article-title>Genes that Control Vaccinia Virus Immunogenicity</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Shchelkunov</surname><given-names>S. N.</given-names></name><xref ref-type="aff" rid="AF1"/><xref ref-type="aff" rid="AF2"/><xref ref-type="aff" rid="AF3"/><email>snshchel@rambler.ru;snshchel@vector.nsc.ru</email></contrib><contrib contrib-type="author"><name><surname>Shchelkunova</surname><given-names>G. A.</given-names></name><xref ref-type="aff" rid="AF1"/></contrib></contrib-group><aff id="AF1">State Research Center of Virology and Biotechnology &#x0201c;Vector&#x0201d;, Rospotrebnadzor, Novosibirsk region, Koltsovo, 630559 Russia </aff><aff id="AF2">The Federal Research Center Institute of Cytology and Genetics, Siberian Branch, Russian Academy of Sciences, Novosibirsk, 630090 Russia </aff><aff id="AF3">Novosibirsk State University, Novosibirsk, 630090 Russia</aff><pub-date pub-type="ppub"><season>Jan-Mar</season><year>2020</year></pub-date><volume>12</volume><issue>1</issue><fpage>33</fpage><lpage>41</lpage><history><date date-type="received"><day>16</day><month>9</month><year>2019</year></date><date date-type="accepted"><day>13</day><month>1</month><year>2020</year></date></history><permissions><copyright-statement>Copyright &#x000ae; 2020 National Research University Higher School of Economics.</copyright-statement><copyright-year>2020</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0/"><license-p>
This is an open-access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.
</license-p></license></permissions><abstract><p>
The live smallpox vaccine was a historical first and highly effective vaccine.
However, along with high immunogenicity, the vaccinia virus (VACV) caused
serious side effects in vaccinees, sometimes with lethal outcomes. Therefore,
after global eradication of smallpox, VACV vaccination was stopped. For this
reason, most of the human population worldwide lacks specific immunity against
not only smallpox, but also other zoonotic orthopoxviruses. Outbreaks of
diseases caused by these viruses have increasingly occurred in humans on
different continents. However, use of the classical live VACV vaccine for
prevention against these diseases is unacceptable because of potential serious
side effects, especially in individuals with suppressed immunity or
immunodeficiency (e.g., HIV-infected patients). Therefore, highly attenuated
VACV variants that preserve their immunogenicity are needed. This review
discusses current ideas about the development of a humoral and cellular immune
response to orthopoxvirus infection/vaccination and describes genetic
engineering approaches that could be utilized to generate safe and highly
immunogenic live VACV vaccines.
</p></abstract><kwd-group kwd-group-type="author"><kwd>smallpox</kwd><kwd>vaccination</kwd><kwd>immunogenicity</kwd><kwd>protectiveness</kwd><kwd>immune modulating proteins</kwd></kwd-group></article-meta></front><body><sec><title>INTRODUCTION</title><p>
The emergence and development of vaccinology was primarily associated with the
search for ways to protect against diseases such as smallpox (Latin
<italic>variola</italic>), a particularly dangerous infection that causes
epidemics with a mortality rate of up to 40% or more in infected patients.
Smallpox survivors were easily identified by the characteristic scars on their
face skin (the so-called &#x0201c;pitted face&#x0201d;), which were left on the
sites of pustules after the loss of dry crusts; these people became immune to
smallpox whenever a new outbreak of the disease occurred. Apparently, these
observations formed the basis for the inoculation of infectious material
obtained by collecting skin crusts from smallpox patients into skin incisions
(usually in the forearm), or intranasally, made on healthy people in India and
China. This procedure, called <italic>variolation</italic> (from variola
inoculation), caused a moderately severe disease and provided further reliable
protection against smallpox. However, 0.5 to 2% of variolated patients would
die, which prevented widespread use of this procedure
[<xref rid="R1" ref-type="bibr">1</xref>].
</p><p>
In 1798, English physician Edward Jenner described a new, safer procedure for
protecting against smallpox [<xref rid="R1" ref-type="bibr">1</xref>, <xref rid="R2" ref-type="bibr">2</xref>]. Rural residents who got infected by animals
which had a smallpox-like disease (cows or horses) were known to have pustular
skin lesions on their hands; they suffered a mild infection that left scars
phenotypically resembling those after variolation. In addition, people who had
contracted cowpox were known to have become immune to smallpox. In 1796, E.
Jenner performed the first experiment in which an eight-year-old child was
inoculated intradermally with material from a pustule collected from a
cowpox-infected woman. To prove that the child had become resistant to smallpox
after the infection, Jenner variolated the child after 6 weeks and found that
the boy was resistant to this procedure.
</p><p>
Given these findings, to emphasize the protective effect of the used infectious
entity against smallpox, Jenner introduced the term &#x0201c;variolae
vaccinae&#x0201d; (Latin for cowpox; from Latin vacca (cow)) instead of the term
cowpox and called the procedure &#x0201c;vaccine inoculation.&#x0201d; In 1803,
Richard Dunning proposed the shortened term &#x0201c;vaccination.&#x0201d; In 1881,
at the 7<sup>th</sup> International Congress of Medicine in London, Louis
Pasteur suggested using the term <italic>vaccination </italic>for all
protective immunization procedures against any infectious disease
[<xref rid="R2" ref-type="bibr">2</xref>].
</p><p>
It should be noted that the kingdom of viruses was discovered a century after
the introduction of Jennerian vaccination. The first animal virus (the foot and
mouth disease virus) was identified only in 1898. The causative agents of
smallpox and cowpox proved to be the largest mammalian viruses. Unlike other
viruses, their virions, after special staining, had been observed as
&#x0201c;elementary particles&#x0201d; under a light microscope as early as 1886;
however, the infectious nature of the particles was proven only in 1931
[<xref rid="R1" ref-type="bibr">1</xref>].
</p><p>
For many years, the variolae vaccinae virus introduced in vaccination by E.
Jenner was believed to originate from the cowpox virus (CPXV) [<xref rid="R1" ref-type="bibr">1</xref>, <xref rid="R3" ref-type="bibr">3</xref>]. In
1939, it was found that strains of the virus used for Jennerian vaccination
significantly differed in properties from natural CPXV isolates derived from
cows [<xref rid="R4" ref-type="bibr">4</xref>]. Therefore, they were assigned
to a separate species, <italic>Vaccinia virus </italic>(VACV) [<xref rid="R1" ref-type="bibr">1</xref>, <xref rid="R3" ref-type="bibr">3</xref>].
The issue of the VACV origin was clarified after the sequencing of the complete
genome of a horsepox virus (HSPV) in 2006 [<xref rid="R5" ref-type="bibr">5</xref>], which turned out to be closely related to the studied VACV
isolates. It is worth noting that E. Jenner considered horses with the pox-like
disease to be a source of infection for cows [<xref rid="R1" ref-type="bibr">1</xref>-<xref rid="R3" ref-type="bibr">3</xref>]. On that basis, it
may be assumed that VACV originated from zoonotic HSPV. Apparently, it was
HSPV&#x02013; not CPXV&#x02013;isolates that were used for Jennerian vaccination in
the 19th century. Their descendants were classified as VACV species in the 20th
century [<xref rid="R6" ref-type="bibr">6</xref>].
</p><p>
It should be noted that, because of lack of knowledge as to the infectious
agent nature and mechanisms for protecting a person from smallpox after vaccine
inoculation, E. Jenner, in his study published in 1801, predicted that
&#x0201c;the annihilation of the smallpox, the most dreadful scourge of the human
species, must be the final result of this practice&#x0201d; [<xref rid="R1" ref-type="bibr">1</xref>]. Today we know that the etiological agents
of smallpox, cowpox, and horsepox are closely related viruses that belong to
the genus<italic> Orthopoxvirus </italic>of the <italic>Poxviridae
</italic>family. Orthopoxviruses are antigenically close to each other, yield
cross serological reactions, and provide an immune defense. The variola virus
(VARV) reproduces only in humans, while CPXV, HSPV, and VACV are zoonotic
viruses with a wide range of susceptible animals, including humans [<xref rid="R3" ref-type="bibr">3</xref>, <xref rid="R6" ref-type="bibr">6</xref>].
Thanks to the international campaign for strict epidemiological surveillance of
smallpox, as well as smallpox vaccination carried out under the auspices of the
World Health Organization (WHO) since 1958, smallpox was completely eradicated
and the last natural case of the disease was encountered in October 1977 [<xref rid="R1" ref-type="bibr">1</xref>]. With that, E. Jenner&#x02019;s intuitive
foresight came true. That great achievement of medicine has led to millions of
lives being saved.
</p><p>
The eradication of smallpox occurred before the advent of modern practices in
virology, immunology, and molecular biology; since there are no animals
susceptible to VARV, the development of a protective immune response to
smallpox has had to be studied indirectly in surrogate models of smallpox
infection. These models include the infection of mice with the mousepox virus
(ectromelia, ECTV) or VACV; rabbits with the rabbitpox virus (RPXV) or VACV;
monkeys with the monkeypox virus (MPXV), etc. Common patterns of a specific
immune response have also been studied using smallpox vaccination of volunteers
with VACV [<xref rid="R7" ref-type="bibr">7</xref>-<xref rid="R9" ref-type="bibr">9</xref>].
</p><p>
Poxviruses are unique among DNA-containing animal viruses, because their entire
cycle of reproduction occurs in the cellular cytoplasm in isolated structures
called viral factories or virosomes. Brick-shaped virions have rounded faces
and are 250&#x02013;300 &#x000d7; 200 &#x000d7; 250 nm in size. The viral genome of
orthopoxviruses is double- stranded linear DNA with covalently closed ends
190&#x02013;220 kb in size (depending on the species), that encodes about 200
proteins, about half of which are highly conserved and provide the vital
function of these viruses [<xref rid="R3" ref-type="bibr">3</xref>,
<xref rid="R10" ref-type="bibr">10</xref>-<xref rid="R13" ref-type="bibr">13</xref>].
The main infectious form of these viruses is the so-called intracellular mature
virion (IMV)
(<italic><xref ref-type="fig" rid="F1">Figure</xref></italic>)
that consists of a nucleoprotein core
containing the viral genome, a complete transcription system for early viral
genes, some other enzymes, lateral protein bodies, and the lipoprotein membrane
covering the particle [<xref rid="R8" ref-type="bibr">8</xref>,
<xref rid="R14" ref-type="bibr">14</xref>, <xref rid="R15" ref-type="bibr">15</xref>].
Mass spectrometry studies demonstrated that VACV IMV
includes 85 different viral proteins, with more than
20 of them being associated with the surface membrane
[<xref rid="R15" ref-type="bibr">15</xref>-<xref rid="R18" ref-type="bibr">18</xref>].
A small part of the newly synthesized viral particles are coated with an additional lipoprotein
envelope; these extracellular enveloped virions (EEVs)
(<italic><xref ref-type="fig" rid="F1">Figure</xref></italic>)
leave infected cells by exocytosis. EEVs contain an
additional eight viral proteins associated with the outer shell
[<xref rid="R8" ref-type="bibr">8</xref>].
</p><fig id="F1" orientation="portrait" position="float"><label>Figure</label><caption><p>
Morphology of intracellular mature (IMV) and extracellular enveloped (EEV)
orthopoxvirus virions [<xref rid="R14" ref-type="bibr">14</xref>] (ViralZone
2008, with permission from the SIB Swiss Institute of Bioinformatics)
</p></caption><graphic xlink:href="AN20758251-12-01-033-g001"/></fig><p>
Both live and inactivated VACV vaccines contain mainly IMV particles obtained
after the destruction of infected cells and purification of viral preparations.
It should be noted that antibodies to both IMV and EEV antigens are induced
only when VACV reproduces in the body of an animal. Furthermore, only a live
virus in the body of the animal induces the synthesis of protective antibodies
to non-virion proteins and stimulates a cellular immune response. That is why
inactivated VACV vaccines do not provide complete antiviral protection
[<xref rid="R8" ref-type="bibr">8</xref>, <xref rid="R19" ref-type="bibr">19</xref>].
</p></sec><sec><title>ANTIBODIES SYNTHESIZED IN RESPONSE TO VACV VACCINATION</title><p>
The antibody response to smallpox vaccination is known to play a crucial role
in the protection against a subsequent viral infection [<xref rid="R8" ref-type="bibr">8</xref>, <xref rid="R9" ref-type="bibr">9</xref>, <xref rid="R20" ref-type="bibr">20</xref>]. Reliable protection against a smallpox
infection was shown to be provided at a virus-neutralizing antibody titer in
the blood serum of vaccinated people above 1:32 [<xref rid="R21" ref-type="bibr">21</xref>]. In humoral immunity defects, vaccination may not provide
smallpox protection. In a B-cell-deficient mouse model, animals were shown not
to be able to withstand ECTV re-infection despite noticeable activity of
antiviral CD8<sup>+</sup> T cells [<xref rid="R22" ref-type="bibr">22</xref>].
</p><p>
In most cases, VARV and VACV virion proteins have a high identity of amino acid
sequences (93&#x02013;99%) [<xref rid="R10" ref-type="bibr">10</xref>, <xref rid="R12" ref-type="bibr">12</xref>], which ensures the high cross-antibody
response of these viruses. However, a comprehensive analysis of some individual
immunodominant viral proteins revealed differences between these viruses in the
profile of induced antibodies. For example, the EEV VACV B5 envelope protein
and its homolog, VARV B7, exhibit 23 amino acid differences (93.06% identity)
[<xref rid="R10" ref-type="bibr">10</xref>], and polyclonal antibodies to VACV
B5 cross-react with the VARV B7 homolog. However, out of the 26 monoclonal
antibodies to B5, only 16 reacted with the homologous VARV protein in
[<xref rid="R23" ref-type="bibr">23</xref>].
</p><p>
Huw Davies et al. [<xref rid="R24" ref-type="bibr">24</xref>] used microchips
with VACV proteins synthesized in a bacterial cell-free system to characterize
the profiles of the humoral immune response to vaccination of volunteers with
live VACV. The vaccinees were found to develop an antibody response to 47
different viral proteins, with significant individual variations both in the
spectrum of antigens and in the production level of antibodies to specific
antigens. The results of this and other studies summarized
in <italic><xref rid="T1" ref-type="table">Table 1</xref></italic> show
numerous viral antigens that often induce a pronounced humoral
immune response. This diversity of antigens is believed to indicate redundancy
and plasticity of the antibody response in vaccinees, and the presence of
antibodies to a large number of antigens creates a &#x0201c;safety network&#x0201d;
that provides effective antiviral protection despite individual differences in
the spectrum of the produced antibodies
[<xref rid="R25" ref-type="bibr">25</xref>, <xref rid="R26" ref-type="bibr">26</xref>].
</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><p>
Main VACV antigens that induced antibody synthesis in more than 25% of
vaccinated volunteers [<xref rid="R15" ref-type="bibr">15</xref>, <xref rid="R24" ref-type="bibr">24</xref>&#x02013;<xref rid="R26" ref-type="bibr">26</xref>]
</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">
Viral antigen<sup>1</sup></th><th rowspan="1" colspan="1">
Synthesis time<sup>2</sup></th><th rowspan="1" colspan="1">Function</th><th rowspan="1" colspan="1">Localization in virion</th><th rowspan="1" colspan="1">
Number of<break/>tested donors
</th><th rowspan="1" colspan="1">
Antigen-specific<break/>antibodies,<break/>detection %<sup>3</sup></th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">A10</td><td align="center" rowspan="1" colspan="1">L</td><td align="center" rowspan="1" colspan="1">Structural</td><td align="center" rowspan="1" colspan="1">Core</td><td align="center" rowspan="1" colspan="1">73</td><td align="center" rowspan="1" colspan="1">93.2</td></tr><tr><td align="center" rowspan="1" colspan="1">H3</td><td align="center" rowspan="1" colspan="1">L</td><td align="center" rowspan="1" colspan="1">Structural</td><td align="center" rowspan="1" colspan="1">IMV membrane</td><td align="center" rowspan="1" colspan="1">336</td><td align="center" rowspan="1" colspan="1">90.5</td></tr><tr><td align="center" rowspan="1" colspan="1">B5</td><td align="center" rowspan="1" colspan="1">E/L</td><td align="center" rowspan="1" colspan="1">Structural</td><td align="center" rowspan="1" colspan="1">EEV envelope</td><td align="center" rowspan="1" colspan="1">287</td><td align="center" rowspan="1" colspan="1">88.5</td></tr><tr><td align="center" rowspan="1" colspan="1">A33</td><td align="center" rowspan="1" colspan="1">L</td><td align="center" rowspan="1" colspan="1">Structural</td><td align="center" rowspan="1" colspan="1">EEV envelope</td><td align="center" rowspan="1" colspan="1">155</td><td align="center" rowspan="1" colspan="1">72.9</td></tr><tr><td align="center" rowspan="1" colspan="1">A27</td><td align="center" rowspan="1" colspan="1">L</td><td align="center" rowspan="1" colspan="1">Structural</td><td align="center" rowspan="1" colspan="1">IMV membrane</td><td align="center" rowspan="1" colspan="1">336</td><td align="center" rowspan="1" colspan="1">67.6</td></tr><tr><td align="center" rowspan="1" colspan="1">A56</td><td align="center" rowspan="1" colspan="1">E/L</td><td align="center" rowspan="1" colspan="1">Structural</td><td align="center" rowspan="1" colspan="1">EEV envelope</td><td align="center" rowspan="1" colspan="1">155</td><td align="center" rowspan="1" colspan="1">63.9</td></tr><tr><td align="center" rowspan="1" colspan="1">
WR148<sup>4</sup></td><td align="center" rowspan="1" colspan="1">L</td><td align="center" rowspan="1" colspan="1">Non-structural</td><td align="center" rowspan="1" colspan="1">Truncated (soluble) ATI protein form</td><td align="center" rowspan="1" colspan="1">70</td><td align="center" rowspan="1" colspan="1">62.9</td></tr><tr><td align="center" rowspan="1" colspan="1">D8</td><td align="center" rowspan="1" colspan="1">L</td><td align="center" rowspan="1" colspan="1">Structural</td><td align="center" rowspan="1" colspan="1">IMV membrane</td><td align="center" rowspan="1" colspan="1">124</td><td align="center" rowspan="1" colspan="1">46</td></tr><tr><td align="center" rowspan="1" colspan="1">D13</td><td align="center" rowspan="1" colspan="1">L</td><td align="center" rowspan="1" colspan="1">Non-structural</td><td align="center" rowspan="1" colspan="1">Enabling IMV assembly</td><td align="center" rowspan="1" colspan="1">124</td><td align="center" rowspan="1" colspan="1">46</td></tr><tr><td align="center" rowspan="1" colspan="1">A13</td><td align="center" rowspan="1" colspan="1">L</td><td align="center" rowspan="1" colspan="1">Structural</td><td align="center" rowspan="1" colspan="1">IMV membrane</td><td align="center" rowspan="1" colspan="1">123</td><td align="center" rowspan="1" colspan="1">39</td></tr><tr><td align="center" rowspan="1" colspan="1">A11</td><td align="center" rowspan="1" colspan="1">L</td><td align="center" rowspan="1" colspan="1">Non-structural</td><td align="center" rowspan="1" colspan="1">Enabling IMV assembly</td><td align="center" rowspan="1" colspan="1">74</td><td align="center" rowspan="1" colspan="1">37.8</td></tr><tr><td align="center" rowspan="1" colspan="1">I1</td><td align="center" rowspan="1" colspan="1">L</td><td align="center" rowspan="1" colspan="1">Structural</td><td align="center" rowspan="1" colspan="1">Core</td><td align="center" rowspan="1" colspan="1">124</td><td align="center" rowspan="1" colspan="1">37.1</td></tr><tr><td align="center" rowspan="1" colspan="1">L1</td><td align="center" rowspan="1" colspan="1">L</td><td align="center" rowspan="1" colspan="1">Structural</td><td align="center" rowspan="1" colspan="1">IMV membrane</td><td align="center" rowspan="1" colspan="1">205</td><td align="center" rowspan="1" colspan="1">31.2</td></tr><tr><td align="center" rowspan="1" colspan="1">A26</td><td align="center" rowspan="1" colspan="1">L</td><td align="center" rowspan="1" colspan="1">Structural</td><td align="center" rowspan="1" colspan="1">IMV membrane</td><td align="center" rowspan="1" colspan="1">123</td><td align="center" rowspan="1" colspan="1">29.3</td></tr><tr><td align="center" rowspan="1" colspan="1">L4</td><td align="center" rowspan="1" colspan="1">L</td><td align="center" rowspan="1" colspan="1">Structural</td><td align="center" rowspan="1" colspan="1">Core</td><td align="center" rowspan="1" colspan="1">73</td><td align="center" rowspan="1" colspan="1">28.8</td></tr><tr><td align="center" rowspan="1" colspan="1">F13</td><td align="center" rowspan="1" colspan="1">L</td><td align="center" rowspan="1" colspan="1">Structural</td><td align="center" rowspan="1" colspan="1">EEV envelope</td><td align="center" rowspan="1" colspan="1">73</td><td align="center" rowspan="1" colspan="1">27.4</td></tr><tr><td align="center" rowspan="1" colspan="1">A14</td><td align="center" rowspan="1" colspan="1">L</td><td align="center" rowspan="1" colspan="1">Structural</td><td align="center" rowspan="1" colspan="1">IMV membrane</td><td align="center" rowspan="1" colspan="1">124</td><td align="center" rowspan="1" colspan="1">26.6</td></tr></tbody></table><table-wrap-foot><fn id="TF1-1"><p>
<sup>1</sup>Proteins names are given according to the nomenclature of VACV,
strain Copenhagen [<xref rid="R10" ref-type="bibr">10</xref>].
</p></fn><fn id="TF1-2"><p>
<sup>2</sup>E/L &#x02013; early-late, L &#x02013; late protein production.
</p></fn><fn id="TF1-3"><p>
<sup>3</sup>Percentage of volunteers with antibodies specific to a given antigen.
</p></fn><fn id="TF1-4"><p>
<sup>4</sup>Nomenclature of VACV, strain WR. The gene of this protein was
deleted in the Copenhagen VACV strain [<xref rid="R3" ref-type="bibr">3</xref>].
</p></fn></table-wrap-foot></table-wrap><p>
Antibody biosynthesis is induced primarily in response to virion proteins whose
genes are expressed at the late stage of the VACV development cycle
(<italic><xref rid="T1" ref-type="table">Table 1</xref></italic>).
To date, eight proteins (H3, B5, D8, L1, A17, A27, A28, and A33) have been
identified as antigens that induce the production of virus-neutralizing antibodies
[<xref rid="R8" ref-type="bibr">8</xref>, <xref rid="R25" ref-type="bibr">25</xref>,
<xref rid="R27" ref-type="bibr">27</xref>-<xref rid="R29" ref-type="bibr">29</xref>].
Involvement of other viral antigens in the development of a protective immune response
has not been sufficiently studied. This indicates the incompleteness of our knowledge
about the development of a humoral immune response to a smallpox
immunization/orthopoxvirus infection.
</p></sec><sec><title>VACV-INDUCED CYTOTOXIC T-LYMPHOCYTES</title><p>
The complex organization of orthopoxviruses is the reason why the mechanism of
immune defense against smallpox (and other orthopoxvirus infections) remains
not fully understood. Along with the induction of virus- specific antibodies,
the response of CD8<sup>+</sup> cytotoxic T-lymphocytes (CTLs) plays an
important role in any control of the infection. A generalized VACV infection
(progressive vaccinia) can develop in primary vaccinated people with T-cell
immunity defects, while this does not occur in the case of an impaired
synthesis of gamma globulins, which indicates the need for a cellular
immune response in order to control a primary infection with this virus
[<xref rid="R8" ref-type="bibr">8</xref>].
</p><p>
As demonstrated in a model of mice pre-infected with an avirulent ECTV strain,
antiviral antibodies are necessary and sufficient to prevent the death of
animals re-infected with a highly virulent ECTV and the absence of a T-cell
immune response does not affect the survival of mice [<xref rid="R30" ref-type="bibr">30</xref>]. In mice with B-cell deficiency (antibody synthesis), VACV
infection of pre-vaccinated animals was shown to be accompanied by a decrease
in body weight, as in unvaccinated mice, but an induction of virus-specific
CTLs prevented death and led to a late recovery [<xref rid="R20" ref-type="bibr">20</xref>]. This response to re-infection may be explained by the
fact that the pre-existing antibodies induced by vaccination can quickly
neutralize the infecting virus, while reactivation of the virus-specific T
cells generated after vaccination takes several days. Although CD8<sup>+</sup>
T cells are important for circumscribing a primary orthopoxvirus infection,
antibodies play a dominant role in the protection against re-infection
(infection after vaccination).
</p><p>
In early studies of the CTL response to orthopoxvirus infection/vaccination,
researchers focused only on a limited number of antigens. Oseroff et al.
[<xref rid="R31" ref-type="bibr">31</xref>] performed a bioinformatic sequence
analysis of all VACV proteins and pinpointed 6,055 potential peptide T-cell
epitopes that were synthesized and used in the analysis of the peripheral blood
mononuclear cells of 31 vaccinated volunteers. They identified 48 epitopes from
35 different VACV proteins which effectively interacted with CD8<sup>+</sup>
T-cells of vaccinees. Subsequent studies identified additional orthopoxvirus T
antigens [<xref rid="R26" ref-type="bibr">26</xref>, <xref rid="R32" ref-type="bibr">32</xref>,
<xref rid="R33" ref-type="bibr">33</xref>]. As in the case
of antibody biosynthesis, the spectrum of orthopoxvirus antigens inducing a CTL
response upon infection/vaccination of humans or animals is characterized by
significant individual differences [<xref rid="R26" ref-type="bibr">26</xref>,
<xref rid="R33" ref-type="bibr">33</xref>]. Viral proteins inducing the most
common CD8<sup>+</sup> T-cell responses in vaccinated individuals are given in
<italic><xref rid="T2" ref-type="table">Table 2</xref></italic>.
The vast majority of these proteins are synthesized at the early stage of the
viral infection; however, a CTL response to some late viral proteins is sometimes detected
[<xref rid="R26" ref-type="bibr">26</xref>, <xref rid="R33" ref-type="bibr">33</xref>].
</p><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><p>
Main VACV antigens that induced production of CD8<sup>+</sup> T cells in
vaccinated volunteers [<xref rid="R3" ref-type="bibr">3</xref>, <xref rid="R26" ref-type="bibr">26</xref>, <xref rid="R31" ref-type="bibr">31</xref>&#x02013;<xref rid="R33" ref-type="bibr">33</xref>]
</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">
Viral<break/>antigen<sup>1</sup></th><th rowspan="1" colspan="1">
Synthesis<break/>time<sup>2</sup></th><th rowspan="1" colspan="1">Function</th><th rowspan="1" colspan="1">
Number<break/>of tested<break/>donors
</th><th rowspan="1" colspan="1">
Percentage of<break/>detected antigen-<break/>specific T cells<sup>3</sup></th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">D12</td><td align="center" rowspan="1" colspan="1">E</td><td align="center" rowspan="1" colspan="1">Small subunit of the mRNA capping enzyme</td><td align="center" rowspan="1" colspan="1">81</td><td align="center" rowspan="1" colspan="1">22.2</td></tr><tr><td align="center" rowspan="1" colspan="1">C7</td><td align="center" rowspan="1" colspan="1">E</td><td align="center" rowspan="1" colspan="1">Inhibition of activity of cellular antiviral factor SAMD9</td><td align="center" rowspan="1" colspan="1">119</td><td align="center" rowspan="1" colspan="1">18.5</td></tr><tr><td align="center" rowspan="1" colspan="1">A47</td><td align="center" rowspan="1" colspan="1">IE</td><td align="center" rowspan="1" colspan="1">Unknown</td><td align="center" rowspan="1" colspan="1">44</td><td align="center" rowspan="1" colspan="1">18.2</td></tr><tr><td align="center" rowspan="1" colspan="1">A8</td><td align="center" rowspan="1" colspan="1">IE</td><td align="center" rowspan="1" colspan="1">Intermediate transcription factor</td><td align="center" rowspan="1" colspan="1">68</td><td align="center" rowspan="1" colspan="1">16.2</td></tr><tr><td align="center" rowspan="1" colspan="1">O1</td><td align="center" rowspan="1" colspan="1">IE</td><td align="center" rowspan="1" colspan="1">Activation of extracellular signal-regulated kinase ERK1/2</td><td align="center" rowspan="1" colspan="1">75</td><td align="center" rowspan="1" colspan="1">16.0</td></tr><tr><td align="center" rowspan="1" colspan="1">J6</td><td align="center" rowspan="1" colspan="1">E</td><td align="center" rowspan="1" colspan="1">147 kDa subunit of viral RNA polymerase</td><td align="center" rowspan="1" colspan="1">80</td><td align="center" rowspan="1" colspan="1">13.8</td></tr><tr><td align="center" rowspan="1" colspan="1">D5</td><td align="center" rowspan="1" colspan="1">E</td><td align="center" rowspan="1" colspan="1">Nucleoside triphosphatase</td><td align="center" rowspan="1" colspan="1">154</td><td align="center" rowspan="1" colspan="1">13.6</td></tr><tr><td align="center" rowspan="1" colspan="1">M1</td><td align="center" rowspan="1" colspan="1">E</td><td align="center" rowspan="1" colspan="1">Ankyrin-like</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">13.3</td></tr><tr><td align="center" rowspan="1" colspan="1">D1</td><td align="center" rowspan="1" colspan="1">E</td><td align="center" rowspan="1" colspan="1">Large subunit of the mRNA-capping enzyme</td><td align="center" rowspan="1" colspan="1">183</td><td align="center" rowspan="1" colspan="1">13.1</td></tr><tr><td align="center" rowspan="1" colspan="1">I8</td><td align="center" rowspan="1" colspan="1">E</td><td align="center" rowspan="1" colspan="1">Nucleoside triphosphate phosphohydrolase</td><td align="center" rowspan="1" colspan="1">70</td><td align="center" rowspan="1" colspan="1">12.8</td></tr><tr><td align="center" rowspan="1" colspan="1">C10</td><td align="center" rowspan="1" colspan="1">E</td><td align="center" rowspan="1" colspan="1">Blocking of IL-1 receptors</td><td align="center" rowspan="1" colspan="1">71</td><td align="center" rowspan="1" colspan="1">12.7</td></tr><tr><td align="center" rowspan="1" colspan="1">C12</td><td align="center" rowspan="1" colspan="1">E</td><td align="center" rowspan="1" colspan="1">Serine protease inhibitor, SPI-1</td><td align="center" rowspan="1" colspan="1">79</td><td align="center" rowspan="1" colspan="1">11.4</td></tr><tr><td align="center" rowspan="1" colspan="1">B6</td><td align="center" rowspan="1" colspan="1">E</td><td align="center" rowspan="1" colspan="1">Unknown</td><td align="center" rowspan="1" colspan="1">45</td><td align="center" rowspan="1" colspan="1">11.1</td></tr><tr><td align="center" rowspan="1" colspan="1">B8</td><td align="center" rowspan="1" colspan="1">E</td><td align="center" rowspan="1" colspan="1">Secreted &#x003b3;-IFN-binding protein</td><td align="center" rowspan="1" colspan="1">120 1</td><td align="center" rowspan="1" colspan="1">10.8</td></tr></tbody></table><table-wrap-foot><fn id="TF2-1"><p>
<sup>1</sup>Proteins names are given according to the nomenclature of VACV,
strain Copenhagen [<xref rid="R10" ref-type="bibr">10</xref>].
</p></fn><fn id="TF2-2"><p>
<sup>2</sup>E &#x02013; early, IE &#x02013; immediate early protein production.
</p></fn><fn id="TF2-3"><p>
<sup>3</sup>Percentage of volunteers with CTLs specific to a given antigen.
</p></fn></table-wrap-foot></table-wrap><p>
It is important to note that the immune CD8 response, on the one hand, and the
CD4/antibody response, on the other hand, respond to different VACV antigens
and involve a broad spectrum of viral proteins
[<xref rid="R26" ref-type="bibr">26</xref>]
(<italic>Tables 1</italic>
and <italic>2</italic>). A
pattern of the immune responses to orthopoxvirus infection/vaccination with
significant personal differences among individuals in the spectrum of antigens
inducing an adaptive immune system response was found not only for these
viruses, but also for the infectious agents <italic>Plasmodium falciparum
</italic>and <italic>Francisella tularensis</italic>
[<xref rid="R24" ref-type="bibr">24</xref>].
All these facts point to the difficult problem of creating effective
inactivated or subunit vaccines for these complex infectious
agents.
</p></sec><sec><title>PREPARATION OF ATTENUATED SMALLPOX VACCINES</title><p>
Because mass smallpox vaccination with VACV caused serious side effects,
sometimes with lethal outcomes, in a small percentage of cases, the WHO, after
the global eradication of smallpox, recommended discontinuation of this
vaccination [<xref rid="R1" ref-type="bibr">1</xref>, <xref rid="R3" ref-type="bibr">3</xref>]. Because of this eschewing of vaccination against smallpox,
most of the human population now lacks specific immunity against not only this
disease, but also other zoonotic orthopoxvirus infections [<xref rid="R6" ref-type="bibr">6</xref>]. That is why unusually massive outbreaks of
orthopoxvirus infections in humans have occurred in various regions throughout
the world in recent years [<xref rid="R34" ref-type="bibr">34</xref>, <xref rid="R35" ref-type="bibr">35</xref>].
</p><p>
The only effective way to combat the growing threat of orthopoxvirus infections
of humans is vaccination [<xref rid="R1" ref-type="bibr">1</xref>, <xref rid="R3" ref-type="bibr">3</xref>]. However, the accumulation of
immunodeficiency states (HIV infection; patients after organ transplantation;
cancer patients, etc.) in recent decades has led to a situation in which mass
vaccination of populations with the classic live VACV vaccine is now
contraindicated. Therefore, there is an urgent need to develop modern live
vaccines that can be much safer compared to the classic smallpox vaccine
[<xref rid="R36" ref-type="bibr">36</xref>, <xref rid="R37" ref-type="bibr">37</xref>].
</p><p>
The modern approach to virus attenuation involves directed inactivation of
virulence genes without affecting the vital virus genes [<xref rid="R38" ref-type="bibr">38</xref>]. The virulence genes primarily include genes whose
products modulate or suppress the numerous mechanisms of innate and/or adaptive
immunity in a virus-infected organism [<xref rid="R39" ref-type="bibr">39</xref>]. Orthopoxviruses are characterized by a uniquely large set
of such genes. In recent years, many of these genes have been identified, and
the properties of the proteins encoded by them have been studied
[<xref rid="R40" ref-type="bibr">40</xref>]. This diversity of virulence genes,
on the one hand, enables the development of different variants of attenuated VACVs
and, on the other hand, increases uncertainty in generating the most effective
and safe vaccine. Each newly developed VACV variant requires numerous
experiments in laboratory animals [<xref rid="R9" ref-type="bibr">9</xref>].
</p><p>
VACV attenuation can often lead to a reduced production of the virus <italic>in
vivo </italic>and, as a consequence, to a reduction in the induced immune
defense of the body. Therefore, an effective antiviral immune response is
achieved by introducing significantly higher doses of the newly created virus,
compared to the original VACV strains, as well as by revaccination
[<xref rid="R41" ref-type="bibr">41</xref>]. The absence of knowledge about the
functions of and interactions between orthopoxvirus immunomodulatory proteins
and the multifactorial mammal immune system results in to a need to use
experimenter intuitive assumptions when choosing mutable genes and combinations
of them to create new, attenuated VACV strains. The
immunogenicity/protectiveness and safety of these strains are tested in various
biological systems. Of greatest interest is genomic editing of VACV, which,
along with attenuation, can enhance the immunogenicity of the generated virus.
</p></sec><sec><title>ENHANCING THE IMMUNOGENICITY OF ATTENUATED SMALLPOX VACCINES</title><p>
In the course of a long evolution, mammals have developed numerous defense
mechanisms against various infectious agents, including viruses. They are
divided into non-specific (innate immunity) and specific (adaptive immunity)
responses to infection.
</p><p>
Non-specific immediate responses are induced after molecular recognition of
conserved microbial components in infected cells and triggering of
intracellular signaling cascades that initiate, through the activation of the
transcription factors NF-&#x003ba;B and/or IRF3, innate immunity responses [<xref rid="R42" ref-type="bibr">42</xref>]. These reactions include cell apoptosis,
inflammatory reactions, chemotaxis of macrophages, natural killer cells (NKs),
and other cell types to the infection site, complement activation, synthesis of
interferons (versatile antiviral proteins), etc. [<xref rid="R39" ref-type="bibr">39</xref>, <xref rid="R40" ref-type="bibr">40</xref>]. B cell
lymphoma-2-like (Bcl2-like) proteins inhibit/modulate the activation of
pro-inflammatory transcription factors and/or apoptosis [<xref rid="R40" ref-type="bibr">40</xref>].
</p><p>
The adaptive immune response to infection, which develops over several days, is
a complex interaction of various cells which is controlled by cytokines and
results in the emergence of B-cells producing specific antiviral antibodies and
the generation of virus-specific CTLs. Antibodies interact with viral particles
and their components, alone or in combination with the complement, and
inactivate them. Cytotoxic CD8<sup>+</sup> T-cells cause lysis of infected
cells [<xref rid="R9" ref-type="bibr">9</xref>, <xref rid="R39" ref-type="bibr">39</xref>].
</p><p>
Orthopoxviruses, in the course of co-evolution with sensitive animals, have
developed various molecular mechanisms to suppress different stages of innate
and adaptive immune response to infection. They encode numerous intracellular
proteins that inhibit the development of apoptosis and different stages of
molecular signaling pathways that induce the production of interferons,
pro-inflammatory cytokines, chemokines, and extracellularly secreted proteins
that interact and neutralize the activity of interferons, complement, and
various cytokines and chemokines [<xref rid="R39" ref-type="bibr">39</xref>,
<xref rid="R40" ref-type="bibr">40</xref>]. Usually, these proteins are not
vital and have no impact on the efficiency of virus propagation in cell
cultures. Targeted inactivation of the genes of these immunomodulatory proteins
usually leads to attenuated virulent properties for VACV in an <italic>in vivo
</italic>system and, therefore, to its greater safety [<xref rid="R38" ref-type="bibr">38</xref>]. However, it may be assumed that removal of the viral
genes that suppress the immune response to an infection can increase, in some
cases, the immunogenicity of the virus despite a decreased efficiency of virus
propagation <italic>in vivo</italic>.
</p><p>
Numerous studies devoted to the deletion (removal) of the genes of VACV
immunomodulatory factors have revealed some viral genes whose inactivation,
along with attenuation of the virus, increases virus immunogenicity
[<xref rid="R43" ref-type="bibr">43</xref>-<xref rid="R53" ref-type="bibr">53</xref>].
As seen from the data
in <italic><xref rid="T3" ref-type="table">Table 3</xref></italic>,
these genes include early viral genes whose protein products are involved
in the regulation/inhibition of both the innate and adaptive immune response to viral infection.
</p><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><p>
VACV genes the removal of which enhances an antiviral immune (protective) response after vaccination
</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">
Gene COP/WR/IND<sup>1</sup></th><th rowspan="1" colspan="1">
Expression Time<sup>2</sup></th><th rowspan="1" colspan="1">Function</th><th rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">C6L/022L/D9L</td><td align="center" rowspan="1" colspan="1">E</td><td align="center" rowspan="1" colspan="1">Bcl-2-like inhibitor of IRF3 and JAK/STAT activation</td><td align="center" rowspan="1" colspan="1">[<xref rid="R43" ref-type="bibr">43</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">N1L/028L/P1L</td><td align="center" rowspan="1" colspan="1">E/L</td><td align="center" rowspan="1" colspan="1">Bcl-2-like inhibitor of apoptosis and NF-&#x003ba;B activation</td><td align="center" rowspan="1" colspan="1">[<xref rid="R44" ref-type="bibr">44</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">K7R/039R/C4R</td><td align="center" rowspan="1" colspan="1">E</td><td align="center" rowspan="1" colspan="1">Bcl-2-like inhibitor of NF-&#x003ba;B and IRF3 activation</td><td align="center" rowspan="1" colspan="1">[<xref rid="R45" ref-type="bibr">45</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">A52R/178R/&#x02013;</td><td align="center" rowspan="1" colspan="1">E</td><td align="center" rowspan="1" colspan="1">Bcl-2-like inhibitor of NF-&#x003ba;B activation</td><td align="center" rowspan="1" colspan="1">[<xref rid="R46" ref-type="bibr">46</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">&#x02013;/013L/D5L</td><td align="center" rowspan="1" colspan="1">E</td><td align="center" rowspan="1" colspan="1">Secreted IL-18-binding protein</td><td align="center" rowspan="1" colspan="1">[<xref rid="R47" ref-type="bibr">47</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">B16R/197R/&#x02013;</td><td align="center" rowspan="1" colspan="1">E</td><td align="center" rowspan="1" colspan="1">Secreted IL-1&#x003b2;-binding protein</td><td align="center" rowspan="1" colspan="1">[<xref rid="R48" ref-type="bibr">48</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">A41L/166L/A46L</td><td align="center" rowspan="1" colspan="1">E/L</td><td align="center" rowspan="1" colspan="1">Secreted CC chemokine-binding protein</td><td align="center" rowspan="1" colspan="1">[<xref rid="R49" ref-type="bibr">49</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">C3L/025L/D12L</td><td align="center" rowspan="1" colspan="1">E</td><td align="center" rowspan="1" colspan="1">Secreted complement-binding protein</td><td align="center" rowspan="1" colspan="1">[<xref rid="R50" ref-type="bibr">50</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">A35R/158R/&#x02013;</td><td align="center" rowspan="1" colspan="1">E</td><td align="center" rowspan="1" colspan="1">MHC Class II Antigen Presentation Inhibitor</td><td align="center" rowspan="1" colspan="1">[<xref rid="R51" ref-type="bibr">51</xref>, <xref rid="R52" ref-type="bibr">52</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">&#x02013;/169R/&#x02013;</td><td align="center" rowspan="1" colspan="1">E</td><td align="center" rowspan="1" colspan="1">Translation initiation inhibitor</td><td align="center" rowspan="1" colspan="1">[<xref rid="R53" ref-type="bibr">53</xref>]</td></tr></tbody></table><table-wrap-foot><fn id="TF3-1"><p>
<sup>1</sup>Genes are designated in accordance with the nomenclature for VACV
Copenhagen (COP) and Western Reserve (WR) strains and the VARV India-1967
strain (IND) [<xref rid="R3" ref-type="bibr">3</xref>]. A dash denotes the lack
of an appropriate gene.
</p></fn><fn id="TF3-2"><p>
<sup>2</sup>E &#x02013; early, E/L &#x02013; early-late transcription.
</p></fn></table-wrap-foot></table-wrap><p>
VACV encodes numerous intracellular Bcl-2-like proteins that inhibit different
stages of the signaling cascades of the nuclear transcription factor NF-&#x003ba;B
and/or IRF3 activation [<xref rid="R40" ref-type="bibr">40</xref>]. Removal of
the gene of each of the four proteins from this family (C6, N1, K7, and A52)
was shown to lead to increased production of NK cells, enhanced CD8<sup>+</sup>
T-cell immune response to VACV infection, and an increased protective effect
(protectiveness) against re-infection [<xref rid="R43" ref-type="bibr">43</xref>-<xref rid="R46" ref-type="bibr">46</xref>].
</p><p>
Inflammatory processes play an important role in early non-specific protection
of the organism against a viral infection. They develop rapidly to limit virus
dissemination within the first hours and days that follow an infection, while
the adaptive immune response is being erected. Cytokines, such as IL-1&#x003b2;,
IL-18, TNF, and &#x003b3;-interferon, which trigger molecular inflammatory
cascades in a particular chemokine expression, are known to play the key role
in the induction of inflammatory reactions. Chemokines are chemoattractant
cytokines that regulate the migration and effector functions of leukocytes,
which play an important role in inflammatory response development and
protection against pathogens. The complement system consists of more than 20
plasma proteins. The antiviral action mechanisms of the complement system
include neutralization of the virus, lysis of virus-infected cells, and
enhancement of the inflammatory and adaptive immune response
[<xref rid="R40" ref-type="bibr">40</xref>]. A deletion of individual genes encoding
IL-1&#x003b2;, IL-18, chemokine, and complement inhibitors was found not only to
decrease the virulent properties of VACV, but also to enhance the immunogenic
properties of this virus
[<xref rid="R46" ref-type="bibr">46</xref>-<xref rid="R49" ref-type="bibr">49</xref>]
(<italic><xref rid="T3" ref-type="table">Table 3</xref></italic>).
</p><p>
The early intracellular VACV protein A35 was shown to inhibit presentation of
viral antigens by the major histocompatibility complex of class II
[<xref rid="R54" ref-type="bibr">54</xref>, <xref rid="R55" ref-type="bibr">55</xref>].
Removal of the <italic>A35R </italic>gene increases the
production of virus-specific antibodies and enhances the protectiveness of VACV
[<xref rid="R51" ref-type="bibr">51</xref>, <xref rid="R52" ref-type="bibr">52</xref>].
</p><p>
Investigation of the function of the <italic>169R </italic>gene in the VACV WR
strain revealed that the protein encoded by the gene inhibits the initiation of
mRNA translation in an infected cell, without affecting viral mRNA translation
in isolated virosomes. This underlies the wide range of the effects of protein
169, in particular the inhibition of the innate immune response to a viral
infection [<xref rid="R53" ref-type="bibr">53</xref>]. Deletion of the
<italic>169R </italic>gene resulted in enhanced production of pro-inflammatory
cytokines and chemokines, increased lung infiltration by leukocytes, and, as a
result, a stricter CD8<sup>+</sup> T-cell immune response and more effective
antiviral protection against repeated infection upon intranasal infection of
mice with a mutant VACV.
</p><p>
Smallpox survivors are known to acquire lifelong immunity against the disease.
VACV vaccination provided effective protection against this especially
dangerous infection; however, re-vaccination was required to maintain a
reliable level of protection against smallpox for a long period of time
[<xref rid="R1" ref-type="bibr">1</xref>]. In this regard, it is noteworthy that
the causative smallpox agent, VARV, lacks at least four genes in its genome, the
removal of which enhances the antiviral immune response, which involves various
molecular mechanisms (<italic><xref rid="T3" ref-type="table">Table 3</xref></italic>).
</p><p>
There have been more or less successful attempts to obtain attenuated and
highly immunogenic VACV strains using targeted inactivation of several viral
genes.
</p><p>
In the NYVAC strain, a simultaneous deletion of three genes of Bcl-2-like
proteins (<italic>A52R</italic>, <italic>B15R</italic>, and<italic>
K7R</italic>) was shown to enhance the innate immune response in infected mice,
which resulted in increased chemokine production and greater migration of
neutrophils, NK cells, and dendritic cells into the infection site [<xref rid="R46" ref-type="bibr">46</xref>].
</p><p>
Genes encoding IL-18-binding (<italic>C12L</italic>), IL-1&#x003b2;- binding
(<italic>B16R</italic>), and CC-chemokine-binding (<italic>A41L</italic>)
proteins, as well as a Bcl-2-like protein (<italic>A46R</italic>), were deleted
from the VACV MVA strain genome [<xref rid="R56" ref-type="bibr">56</xref>].
The produced VACV variant with four deleted immunomodulatory genes resulted in
a higher level of antiviral antibodies in rhesus monkeys compared to the
initial VACV MVA.
</p><p>
A higher adaptive T-cell immune response was induced by a VACV MVA strain with
intentionally deleted three genes encoding an IL-18 binding protein
(<italic>C12L </italic>or <italic>013L </italic>for VACV WR), a Bcl-2-like
protein (<italic>A46R</italic>), and 3&#x003b2;-hydroxysteroid dehydrogenase
(<italic>A44L</italic>) [<xref rid="R57" ref-type="bibr">57</xref>].
</p><p>
The VACV LIVP strain was used to create a recombinant variant with five
impaired virulence genes encoding hemagglutinin (<italic>A56R</italic>), a
gamma-interferon- binding protein (<italic>B8R</italic>), thymidine kinase
(<italic>J2R</italic>), a complement-binding protein (<italic>C3L</italic>),
and a Bcl-2-like apoptosis inhibitor (<italic>N1L</italic>). Inactivation of
these virulence genes was shown not to affect the reproductive properties of
VACV in mammalian cell cultures. The produced VACV strain was characterized by
significantly lower reactogenicity and neurovirulence compared to those of the
original LIVP. Upon subcutaneous administration to mice, the recombinant VACV
variant induced the production of VACV-neutralizing antibodies at a level
comparable to that of the parental LIVP strain [<xref rid="R38" ref-type="bibr">38</xref>].
To increase the production of virus-specific antibodies,
the <italic>A35R </italic>gene was additionally inactivated
(<italic><xref rid="T3" ref-type="table">Table 3</xref></italic>).
The produced LIVP&#x00394;6 strain induced a significantly higher
level of virus-neutralizing antibodies in mice and provided greater protection
than the original VACV strain [<xref rid="R52" ref-type="bibr">52</xref>].
</p><p>
Given the fact that removal of individual genes of the VACV Bcl-2-like proteins
N1, C6, or K7 not only led to an attenuation of the virus but also increased
its immunogenicity [<xref rid="R43" ref-type="bibr">43</xref>-<xref rid="R45" ref-type="bibr">45</xref>], a VACV WR variant lacking these three
genes was created. The obtained triple VACV mutant did not lose its ability to
efficiently propagate in cell culture, but in the <italic>in vivo
</italic>system it was more attenuated compared to mutants with single
deletions of these genes and caused a decreased production of
virus-neutralizing antibodies and specific CD8<sup>+</sup> T cells [<xref rid="R58" ref-type="bibr">58</xref>].
</p><p>
Summarizing the results of these studies, it may be concluded that the
development of safe and highly immunogenic VACV variants should rest on a
balance between attenuation and immunogenicity. Since our current level of
knowledge does not allow us to predict the results that might be achieved by
the impairment of several target VACV genes, each produced virus variant should
be carefully studied in different model animals.
</p></sec></body><back><ack><p>
This work was supported by the Russian Science Foundation (grant No.
19-14-00006).
</p></ack><glossary><def-list><title>Abbreviations</title><def-item><term id="G01">WHO</term><def><p>World Health Organization</p></def></def-item><def-item><term id="G02">CPXV</term><def><p>cowpox virus</p></def></def-item><def-item><term id="G03">CTL</term><def><p>cytotoxic T lymphocyte</p></def></def-item><def-item><term id="G04">EEV</term><def><p>extracellular enveloped virion</p></def></def-item><def-item><term id="G05">HSPV</term><def><p>horsepox virus</p></def></def-item><def-item><term id="G06">IMV</term><def><p>intracellular mature virion</p></def></def-item><def-item><term id="G07">NK</term><def><p>natural killer</p></def></def-item><def-item><term id="G08">VACV</term><def><p>vaccinia virus</p></def></def-item><def-item><term id="G09">VARV</term><def><p>variola virus</p></def></def-item></def-list></glossary><ref-list><title>References</title><ref id="R1"><label>1</label><element-citation publication-type="book"><source>Smallpox and Its Eradication. Geneva: World Health Organization, 1988. 1460 p.</source><year>1998</year><name><surname>Fenner</surname><given-names>F.</given-names></name><name><surname>Henderson</surname><given-names>D.A.</given-names></name><name><surname>Arita</surname><given-names>I.</given-names></name><name><surname>Jezek</surname><given-names>Z.</given-names></name><name><surname>Ladnyi</surname><given-names>I.D.</given-names></name></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><source>Vaccine.</source><year>2017</year><volume>35</volume><fpage>7222</fpage><lpage>7230</lpage><name><surname>Esparza</surname><given-names>J.</given-names></name><name><surname>Schrick</surname><given-names>L.</given-names></name><name><surname>Damaso</surname><given-names>C.R.</given-names></name><name><surname>Nitsche</surname><given-names>A.</given-names></name><pub-id pub-id-type="pmid">29137821</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="book"><source>Orthopoxviruses pathogenic for humans. New York: Springer, 2005. 425 p.</source><year>2005</year><name><surname>Shchelkunov</surname><given-names>S.N.</given-names></name><name><surname>Marennikova</surname><given-names>S.S.</given-names></name><name><surname>Moyer</surname><given-names>R.W.</given-names></name></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><source>Br. J. Exp. Pathol.</source><year>1939</year><volume>20</volume><fpage>158</fpage><lpage>176</lpage><name><surname>Downie</surname><given-names>A.W.</given-names></name></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><source>Virology Journal</source><year>2006</year><volume>80</volume><fpage>9244</fpage><lpage>9258</lpage><name><surname>Tulman</surname><given-names>E.R.</given-names></name><name><surname>Delhon</surname><given-names>G.</given-names></name><name><surname>Afonso</surname><given-names>C.L.</given-names></name><name><surname>Lu</surname><given-names>Z.</given-names></name><name><surname>Zsak</surname><given-names>L.</given-names></name><name><surname>Sandybaev</surname><given-names>N.T.</given-names></name><name><surname>Kerembekova</surname><given-names>U.Z.</given-names></name><name><surname>Zaitsev</surname><given-names>V.L.</given-names></name><name><surname>Kutish</surname><given-names>G.F.</given-names></name><name><surname>Rock</surname><given-names>D.L.</given-names></name></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><source>PLoS Pathog.</source><year>2013</year><volume>9</volume><elocation-id>e1003756</elocation-id><name><surname>Shchelkunov</surname><given-names>S.N.</given-names></name><pub-id pub-id-type="pmid">24339772</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><source>Curr. Opin. Immunol.</source><year>2009</year><volume>21</volume><fpage>314</fpage><lpage>320</lpage><name><surname>Kennedy</surname><given-names>R.B.</given-names></name><name><surname>Ovsyannikova</surname><given-names>I.G.</given-names></name><name><surname>Jacobson</surname><given-names>R.M.</given-names></name><name><surname>Poland</surname><given-names>G.A.</given-names></name><pub-id pub-id-type="pmid">19524427</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><source>Immunol. Rev.</source><year>2011</year><volume>239</volume><fpage>8</fpage><lpage>26</lpage><name><surname>Moss</surname><given-names>B.</given-names></name><pub-id pub-id-type="pmid">21198662</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><source>Viruses.</source><year>2018</year><volume>10</volume><fpage>e101</fpage><name><surname>Albarnaz</surname><given-names>J.D.</given-names></name><name><surname>Torres</surname><given-names>A.A.</given-names></name><name><surname>Smith</surname><given-names>G.L.</given-names></name><pub-id pub-id-type="pmid">29495547</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><source>Virus Genes.</source><year>1995</year><volume>10</volume><fpage>53</fpage><lpage>71</lpage><name><surname>Shchelkunov</surname><given-names>S.N.</given-names></name><pub-id pub-id-type="pmid">7483290</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><source>Virology</source><year>1998</year><volume>243</volume><fpage>432</fpage><lpage>460</lpage><name><surname>Shchelkunov</surname><given-names>S.N.</given-names></name><name><surname>Safronov</surname><given-names>P.F.</given-names></name><name><surname>Totmenin</surname><given-names>A.V.</given-names></name><name><surname>Petrov</surname><given-names>N.A.</given-names></name><name><surname>Ryazankina</surname><given-names>O.I.</given-names></name><name><surname>Gutorov</surname><given-names>V.V.</given-names></name><name><surname>Kotwal</surname><given-names>G.J.</given-names></name><pub-id pub-id-type="pmid">9568042</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><source>Virology</source><year>2000</year><volume>266</volume><fpage>361</fpage><lpage>386</lpage><name><surname>Shchelkunov</surname><given-names>S.N.</given-names></name><name><surname>Totmenin</surname><given-names>A.V.</given-names></name><name><surname>Loparev</surname><given-names>V.N.</given-names></name><name><surname>Safronov</surname><given-names>P.F.</given-names></name><name><surname>Gutorov</surname><given-names>V.V.</given-names></name><name><surname>Chizhikov</surname><given-names>V.E.</given-names></name><name><surname>Knight</surname><given-names>J.C.</given-names></name><name><surname>Parsons</surname><given-names>J.M.</given-names></name><name><surname>Massung</surname><given-names>R.F.</given-names></name><name><surname>Esposito</surname><given-names>J.J.</given-names></name><pub-id pub-id-type="pmid">10639322</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><source>Virology</source><year>2002</year><volume>509</volume><fpage>66</fpage><lpage>70</lpage><name><surname>Shchelkunov</surname><given-names>S.N.</given-names></name><name><surname>Totmenin</surname><given-names>A.V.</given-names></name><name><surname>Safronov</surname><given-names>P.F.</given-names></name><name><surname>Mikheev</surname><given-names>M.V.</given-names></name><name><surname>Gutorov</surname><given-names>V.V.</given-names></name><name><surname>Ryazankina</surname><given-names>O.I.</given-names></name><name><surname>Petrov</surname><given-names>N.A.</given-names></name><name><surname>Babkin</surname><given-names>I.V.</given-names></name><name><surname>Uvarova</surname><given-names>E.A.</given-names></name><name><surname>Sandakhchiev</surname><given-names>L.S.</given-names></name></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><source>. Nucleic Acids Res.</source><year>2011</year><volume>39</volume><fpage>D576</fpage><lpage>D582</lpage><name><surname>Le</surname><given-names>Mercier P.</given-names></name><pub-id pub-id-type="pmid">20947564</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><source>Adv. Virus. Res.</source><year>2006</year><volume>66</volume><fpage>31</fpage><lpage>124</lpage><name><surname>Condit</surname><given-names>R.C.</given-names></name><name><surname>Moussatche</surname><given-names>N.</given-names></name><name><surname>Traktman</surname><given-names>P.</given-names></name><pub-id pub-id-type="pmid">16877059</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><source>Virology Journal</source><year>2006</year><volume>3</volume><fpage>e10</fpage><name><surname>Yoder</surname><given-names>J.D.</given-names></name><name><surname>Chen</surname><given-names>T.S.</given-names></name><name><surname>Garnier</surname><given-names>C.R.</given-names></name><name><surname>Vemulapalli</surname><given-names>S.</given-names></name><name><surname>Maier</surname><given-names>C.S.</given-names></name><name><surname>Hruby</surname><given-names>D.E.</given-names></name></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><source>Virology Journal</source><year>2006</year><volume>80</volume><fpage>2127</fpage><lpage>2140</lpage><name><surname>Chung</surname><given-names>C.S.</given-names></name><name><surname>Chen</surname><given-names>C.H.</given-names></name><name><surname>Ho</surname><given-names>M.Y.</given-names></name><name><surname>Huang</surname><given-names>C.Y.</given-names></name><name><surname>Liao</surname><given-names>C.L.</given-names></name><name><surname>Chang</surname><given-names>W.</given-names></name></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><source>Virology</source><year>2007</year><volume>358</volume><fpage>233</fpage><lpage>247</lpage><name><surname>Resch</surname><given-names>W.</given-names></name><name><surname>Hixson</surname><given-names>K.K.</given-names></name><name><surname>Moore</surname><given-names>R.J.</given-names></name><name><surname>Lipton</surname><given-names>M.S.</given-names></name><name><surname>Moss</surname><given-names>D.</given-names></name><pub-id pub-id-type="pmid">17005230</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><source>J. Immunol.</source><year>2019</year><volume>202</volume><fpage>1340</fpage><lpage>1349</lpage><name><surname>Forsyth</surname><given-names>K.S.</given-names></name><name><surname>DeHaven</surname><given-names>B.</given-names></name><name><surname>Mendoca</surname><given-names>M.</given-names></name><name><surname>Paul</surname><given-names>S.</given-names></name><name><surname>Sette</surname><given-names>A.</given-names></name><name><surname>Eisenlohr</surname><given-names>L.C.</given-names></name><pub-id pub-id-type="pmid">30700590</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><source>Proc. Natl. Acad. Sci. USA.</source><year>2003</year><volume>100</volume><fpage>9458</fpage><lpage>9463</lpage><name><surname>Belyakov</surname><given-names>I.M.</given-names></name><name><surname>Earl</surname><given-names>P.</given-names></name><name><surname>Dzutsev</surname><given-names>A.</given-names></name><name><surname>Kuznetsov</surname><given-names>V.A.</given-names></name><name><surname>Lemon</surname><given-names>M.</given-names></name><name><surname>Wyatt</surname><given-names>L.S.</given-names></name><name><surname>Snyder</surname><given-names>J.T.</given-names></name><name><surname>Ahlers</surname><given-names>J.D.</given-names></name><name><surname>Franchini</surname><given-names>G.</given-names></name><name><surname>Moss</surname><given-names>B.</given-names></name><pub-id pub-id-type="pmid">12869693</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><source>Am. J. Trop. Med. Hyg.</source><year>1972</year><volume>21</volume><fpage>214</fpage><lpage>218</lpage><name><surname>Mack</surname><given-names>T.M.</given-names></name><name><surname>Noble</surname><given-names>J.</given-names></name><name><surname>Thomas</surname><given-names>D.B.</given-names></name><pub-id pub-id-type="pmid">5061278</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><source>Virology Journal</source><year>2006</year><volume>80</volume><fpage>6339</fpage><lpage>6344</lpage><name><surname>Chaudhri</surname><given-names>G.</given-names></name><name><surname>Panchanathan</surname><given-names>V.</given-names></name><name><surname>Bluethmann</surname><given-names>H.</given-names></name><name><surname>Karupiah</surname><given-names>G.</given-names></name></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><source>Virology Journal</source><year>2007</year><volume>81</volume><fpage>8131</fpage><lpage>8139</lpage><name><surname>Aldaz-Carroll</surname><given-names>L.</given-names></name><name><surname>Xiao</surname><given-names>Y.</given-names></name><name><surname>Whitbeck</surname><given-names>J.C.</given-names></name><name><surname>de Leon</surname><given-names>M.P.</given-names></name><name><surname>Lou</surname><given-names>H.</given-names></name><name><surname>Kim</surname><given-names>M.</given-names></name><name><surname>Yu</surname><given-names>J.</given-names></name><name><surname>Reinherz</surname><given-names>E.L.</given-names></name><name><surname>Isaacs</surname><given-names>S.N.</given-names></name><name><surname>Eisenberg</surname><given-names>R.J.</given-names></name></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><source>Proteomics.</source><year>2007</year><volume>7</volume><fpage>1678</fpage><lpage>1686</lpage><name><surname>Huw Davies</surname><given-names>D.</given-names></name><name><surname>Molina</surname><given-names>D.M.</given-names></name><name><surname>Wrammer</surname><given-names>J.</given-names></name><name><surname>Miller</surname><given-names>J.</given-names></name><name><surname>Hirst</surname><given-names>S.</given-names></name><name><surname>Mu</surname><given-names>Y.</given-names></name><name><surname>Pablo</surname><given-names>J.</given-names></name><name><surname>Unal</surname><given-names>B.</given-names></name><name><surname>Nakajima-Sasaki</surname><given-names>R.</given-names></name><name><surname>Liang</surname><given-names>X.</given-names></name><pub-id pub-id-type="pmid">17443847</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><source>Virology Journal</source><year>2008</year><volume>82</volume><fpage>3751</fpage><lpage>3768</lpage><name><surname>Benhnia</surname><given-names>M.R.</given-names></name><name><surname>McCausland</surname><given-names>M.M.</given-names></name><name><surname>Su</surname><given-names>H.</given-names></name><name><surname>Singh</surname><given-names>K.</given-names></name><name><surname>Hoffmann</surname><given-names>J.</given-names></name><name><surname>Davies</surname><given-names>D.H.</given-names></name><name><surname>Felgner</surname><given-names>P.L.</given-names></name><name><surname>Head</surname><given-names>S.</given-names></name><name><surname>Sette</surname><given-names>A.</given-names></name><name><surname>Garboczi</surname><given-names>D.N.</given-names></name></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><source>Future Microbiol.</source><year>2010</year><volume>5</volume><fpage>221</fpage><lpage>239</lpage><name><surname>Moutaftsi</surname><given-names>M.</given-names></name><name><surname>Tscharke</surname><given-names>D.C.</given-names></name><name><surname>Vaughan</surname><given-names>K.</given-names></name><name><surname>Koelle</surname><given-names>D.M.</given-names></name><name><surname>Stern</surname><given-names>L.</given-names></name><name><surname>Calvo-Calle</surname><given-names>M.</given-names></name><name><surname>Ennis</surname><given-names>F.</given-names></name><name><surname>Terajima</surname><given-names>M.</given-names></name><name><surname>Sutter</surname><given-names>G.</given-names></name><name><surname>Crotty</surname><given-names>S.</given-names></name><pub-id pub-id-type="pmid">20143946</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><source>Immunol. Rev.</source><year>2006</year><volume>211</volume><fpage>320</fpage><lpage>337</lpage><name><surname>Amanna</surname><given-names>I.J.</given-names></name><name><surname>Slifka</surname><given-names>M.K.</given-names></name><name><surname>Crotty</surname><given-names>S.</given-names></name><pub-id pub-id-type="pmid">16824139</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><source>PLoS Pathog.</source><year>2015</year><volume>11</volume><elocation-id>e1005148</elocation-id><name><surname>Matho</surname><given-names>M.H.</given-names></name><name><surname>Schlossman</surname><given-names>A.</given-names></name><name><surname>Meng</surname><given-names>X.</given-names></name><name><surname>Benhnia</surname><given-names>M.R.</given-names></name><name><surname>Kaever</surname><given-names>T.</given-names></name><name><surname>Buller</surname><given-names>M.</given-names></name><name><surname>Doronin</surname><given-names>K.</given-names></name><name><surname>Parker</surname><given-names>S.</given-names></name><name><surname>Peters</surname><given-names>B.</given-names></name><name><surname>Crotty</surname><given-names>S.</given-names></name><pub-id pub-id-type="pmid">26325270</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><source>Subcell. Biochem.</source><year>2017</year><volume>83</volume><fpage>103</fpage><lpage>126</lpage><name><surname>Zajonc</surname><given-names>D.M.</given-names></name><pub-id pub-id-type="pmid">28271474</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><source>Virology Journal</source><year>2006</year><volume>80</volume><fpage>6333</fpage><lpage>6338</lpage><name><surname>Panchanathan</surname><given-names>V.</given-names></name><name><surname>Chaudhri</surname><given-names>G.</given-names></name><name><surname>Karupiah</surname><given-names>G.</given-names></name></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><source>Proc. Natl. Acad. Sci. USA.</source><year>2005</year><volume>102</volume><fpage>13980</fpage><lpage>13985</lpage><name><surname>Oseroff</surname><given-names>C.</given-names></name><name><surname>Kos</surname><given-names>F.</given-names></name><name><surname>Bui</surname><given-names>H.</given-names></name><name><surname>Peters</surname><given-names>B.</given-names></name><name><surname>Pasquetto</surname><given-names>V.</given-names></name><name><surname>Glenn</surname><given-names>J.</given-names></name><name><surname>Palmore</surname><given-names>T.</given-names></name><name><surname>Sidney</surname><given-names>J.</given-names></name><name><surname>Tscharke</surname><given-names>D.C.</given-names></name><name><surname>Bennink</surname><given-names>J.R.</given-names></name><pub-id pub-id-type="pmid">16172378</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><source>Nat. Biotechnol.</source><year>2006</year><volume>24</volume><fpage>817</fpage><lpage>819</lpage><name><surname>Moutaftsi</surname><given-names>M.</given-names></name><name><surname>Peters</surname><given-names>B.</given-names></name><name><surname>Pasquetto</surname><given-names>V.</given-names></name><name><surname>Tscharke</surname><given-names>D.C.</given-names></name><name><surname>Sidney</surname><given-names>J.</given-names></name><name><surname>Bui</surname><given-names>H.H.</given-names></name><name><surname>Grey</surname><given-names>H.</given-names></name><name><surname>Sette</surname><given-names>A.</given-names></name><pub-id pub-id-type="pmid">16767078</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><source>Proc. Natl. Acad. Sci. USA.</source><year>2019</year><volume>116</volume><fpage>3112</fpage><lpage>3117</lpage><name><surname>Croft</surname><given-names>N.P.</given-names></name><name><surname>Smith</surname><given-names>S.A.</given-names></name><name><surname>Pickering</surname><given-names>J.</given-names></name><name><surname>Sidney</surname><given-names>J.</given-names></name><name><surname>Peters</surname><given-names>B.</given-names></name><name><surname>Faridi</surname><given-names>P.</given-names></name><name><surname>Witney</surname><given-names>M.J.</given-names></name><name><surname>Sebastian</surname><given-names>P.</given-names></name><name><surname>Flesch</surname><given-names>I.E.A.</given-names></name><name><surname>Heading</surname><given-names>S.L.</given-names></name><pub-id pub-id-type="pmid">30718433</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><source>Viruses.</source><year>2017</year><volume>9</volume><elocation-id>e242</elocation-id><name><surname>Olson</surname><given-names>V.A.</given-names></name><name><surname>Shchelkunov</surname><given-names>S.N.</given-names></name></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><source>Expert Rev. Anti. Infect. Ther.</source><year>2019</year><volume>17</volume><fpage>129</fpage><lpage>139</lpage><name><surname>Reynolds</surname><given-names>M.G.</given-names></name><name><surname>Doty</surname><given-names>J.B.</given-names></name><name><surname>McCollum</surname><given-names>A.M.</given-names></name><name><surname>Olson</surname><given-names>V.A.</given-names></name><name><surname>Nakazawa</surname><given-names>Y.</given-names></name><pub-id pub-id-type="pmid">30625020</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><source>Vaccine.</source><year>2011</year><volume>29</volume><issue>4</issue><fpage>D49</fpage><lpage>D53</lpage><name><surname>Shchelkunov</surname><given-names>S.N.</given-names></name><pub-id pub-id-type="pmid">22185833</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><source>Acta Naturae.</source><year>2017</year><volume>9</volume><fpage>4</fpage><lpage>12</lpage><name><surname>Shchelkunova</surname><given-names>G.A.</given-names></name><name><surname>Shchelkunov</surname><given-names>S.N.</given-names></name></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><source>Acta Naturae.</source><year>2015</year><volume>7</volume><fpage>113</fpage><lpage>121</lpage><name><surname>Yakubitskiy</surname><given-names>S.N.</given-names></name><name><surname>Kolosova</surname><given-names>I.V.</given-names></name><name><surname>Maksyutov</surname><given-names>R.A.</given-names></name><name><surname>Shchelkunov</surname><given-names>S.N.</given-names></name></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><source>Mol. Biol.</source><year>2011</year><volume>45</volume><fpage>24</fpage><lpage>35</lpage><name><surname>Shchelkunov</surname><given-names>S.N.</given-names></name></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><source>Adv. Virol.</source><year>2012</year><volume>2012</volume><elocation-id>524743</elocation-id><name><surname>Shchelkunov</surname><given-names>S.N.</given-names></name><pub-id pub-id-type="pmid">22899927</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><source>Vaccine.</source><year>2008</year><volume>26</volume><fpage>1794</fpage><lpage>1804</lpage><name><surname>Ferrier-Rembert</surname><given-names>A.</given-names></name><name><surname>Drillien</surname><given-names>R.</given-names></name><name><surname>Tournier</surname><given-names>J.N.</given-names></name><name><surname>Garin</surname><given-names>D.</given-names></name><name><surname>Crance</surname><given-names>J.M.</given-names></name><pub-id pub-id-type="pmid">18336966</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><source>Mol. Biol.</source><year>2011</year><volume>45</volume><fpage>5</fpage><lpage>15</lpage><name><surname>Drutskaya</surname><given-names>M.S.</given-names></name><name><surname>Belousov</surname><given-names>P.V.</given-names></name><name><surname>Nedospasov</surname><given-names>S.A.</given-names></name></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><source>J. Gen. Virol.</source><year>2013</year><volume>94</volume><fpage>1121</fpage><lpage>1126</lpage><name><surname>Summer</surname><given-names>R.P.</given-names></name><name><surname>Ren</surname><given-names>H.</given-names></name><name><surname>Smith</surname><given-names>G.L.</given-names></name><pub-id pub-id-type="pmid">23288427</pub-id></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal"><source>PLoS One.</source><year>2008</year><volume>3</volume><elocation-id>e3323</elocation-id><name><surname>Mathew</surname><given-names>A.</given-names></name><name><surname>O&#x02019;Bryan</surname><given-names>J.</given-names></name><name><surname>Marshall</surname><given-names>W.</given-names></name><name><surname>Kotwal</surname><given-names>G.J.</given-names></name><name><surname>Terajima</surname><given-names>M.</given-names></name><name><surname>Green</surname><given-names>S.</given-names></name><name><surname>Rothman</surname><given-names>A.L.</given-names></name><name><surname>Ennis</surname><given-names>F.A.</given-names></name><pub-id pub-id-type="pmid">18830408</pub-id></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><source>J. Gen. Virol.</source><year>2013</year><volume>94</volume><fpage>1647</fpage><lpage>1657</lpage><name><surname>Benfield</surname><given-names>C.T.O.</given-names></name><name><surname>Ren</surname><given-names>H.</given-names></name><name><surname>Lucas</surname><given-names>S.J.</given-names></name><name><surname>Bahsoun</surname><given-names>B.</given-names></name><name><surname>Smith</surname><given-names>G.L.</given-names></name><pub-id pub-id-type="pmid">23580427</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="journal"><source>Virology Journal</source><year>2017</year><volume>91</volume><elocation-id>e00575-17</elocation-id><name><surname>Di Pilato</surname><given-names>M.</given-names></name><name><surname>Mejias-Perez</surname><given-names>E.</given-names></name><name><surname>Sorzano</surname><given-names>C.O.S.</given-names></name><name><surname>Esteban</surname><given-names>M.</given-names></name></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal"><source>PLoS One.</source><year>2012</year><volume>7</volume><elocation-id>e32220</elocation-id><name><surname>Falivene</surname><given-names>J.</given-names></name><name><surname>Del Medico Zajac</surname><given-names>M.P.</given-names></name><name><surname>Pascutti</surname><given-names>M.F.</given-names></name><name><surname>Rodriguez</surname><given-names>A.M.</given-names></name><name><surname>Maeto</surname><given-names>C.</given-names></name><name><surname>Perdiguero</surname><given-names>B.</given-names></name><name><surname>Gomez</surname><given-names>C.E.</given-names></name><name><surname>Esteban</surname><given-names>M.</given-names></name><name><surname>Calamante</surname><given-names>G.</given-names></name><name><surname>Gherardi</surname><given-names>M.M.</given-names></name><pub-id pub-id-type="pmid">22384183</pub-id></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal"><source>J. Gen. Virol.</source><year>2005</year><volume>86</volume><fpage>1997</fpage><lpage>2006</lpage><name><surname>Staib</surname><given-names>C.</given-names></name><name><surname>Kisling</surname><given-names>S.</given-names></name><name><surname>Erfle</surname><given-names>V.</given-names></name><name><surname>Sutter</surname><given-names>G.</given-names></name><pub-id pub-id-type="pmid">15958679</pub-id></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal"><source>J. Gen. Virol.</source><year>2006</year><volume>87</volume><fpage>29</fpage><lpage>38</lpage><name><surname>Clark</surname><given-names>R.H.</given-names></name><name><surname>Kenyon</surname><given-names>J.C.</given-names></name><name><surname>Bartlett</surname><given-names>N.W.</given-names></name><name><surname>Tscharke</surname><given-names>D.C.</given-names></name><name><surname>Smith</surname><given-names>G.L.</given-names></name><pub-id pub-id-type="pmid">16361415</pub-id></element-citation></ref><ref id="R50"><label>50</label><element-citation publication-type="journal"><source>Virology Journal</source><year>2011</year><volume>85</volume><fpage>2547</fpage><lpage>2556</lpage><name><surname>Girgis</surname><given-names>N.M.</given-names></name><name><surname>DeHaven</surname><given-names>B.</given-names></name><name><surname>Xiao</surname><given-names>Y.</given-names></name><name><surname>Alexander</surname><given-names>E.</given-names></name><name><surname>Viner</surname><given-names>K.</given-names></name><name><surname>Isaacs</surname><given-names>S.N.</given-names></name></element-citation></ref><ref id="R51"><label>51</label><element-citation publication-type="journal"><source>Vaccine.</source><year>2011</year><volume>29</volume><fpage>3276</fpage><lpage>3283</lpage><name><surname>Rehm</surname><given-names>K.E.</given-names></name><name><surname>Roper</surname><given-names>R.L.</given-names></name><pub-id pub-id-type="pmid">21352940</pub-id></element-citation></ref><ref id="R52"><label>52</label><element-citation publication-type="journal"><source>Dokl. Biochem. Biophys.</source><year>2016</year><volume>466</volume><fpage>35</fpage><lpage>38</lpage><name><surname>Yakubitskyi</surname><given-names>S.N.</given-names></name><name><surname>Kolosova</surname><given-names>I.V.</given-names></name><name><surname>Maksyutov</surname><given-names>R.A.</given-names></name><name><surname>Shchelkunov</surname><given-names>S.N.</given-names></name><pub-id pub-id-type="pmid">27025484</pub-id></element-citation></ref><ref id="R53"><label>53</label><element-citation publication-type="journal"><source>PLoS Pathog.</source><year>2015</year><volume>11</volume><elocation-id>e1005151</elocation-id><name><surname>Strnadova</surname><given-names>P.</given-names></name><name><surname>Ren</surname><given-names>H.</given-names></name><name><surname>Valentine</surname><given-names>R.</given-names></name><name><surname>Mazzon</surname><given-names>M.</given-names></name><name><surname>Sweeney</surname><given-names>T.R.</given-names></name><name><surname>Brierley</surname><given-names>I.</given-names></name><name><surname>Smith</surname><given-names>G.L.</given-names></name><pub-id pub-id-type="pmid">26334635</pub-id></element-citation></ref><ref id="R54"><label>54</label><element-citation publication-type="journal"><source>Immunology.</source><year>2009</year><volume>128</volume><fpage>381</fpage><lpage>392</lpage><name><surname>Rehm</surname><given-names>K.E.</given-names></name><name><surname>Connor</surname><given-names>R.F.</given-names></name><name><surname>Jones</surname><given-names>G.J.B.</given-names></name><name><surname>Yimbu</surname><given-names>K.</given-names></name><name><surname>Mannie</surname><given-names>M.D.</given-names></name><name><surname>Roper</surname><given-names>R.L.</given-names></name><pub-id pub-id-type="pmid">20067538</pub-id></element-citation></ref><ref id="R55"><label>55</label><element-citation publication-type="journal"><source>Virology</source><year>2010</year><volume>397</volume><fpage>176</fpage><lpage>186</lpage><name><surname>Rehm</surname><given-names>K.E.</given-names></name><name><surname>Connor</surname><given-names>R.F.</given-names></name><name><surname>Jones</surname><given-names>G.J.B.</given-names></name><name><surname>Yimbu</surname><given-names>K.</given-names></name><name><surname>Roper</surname><given-names>R.L.</given-names></name><pub-id pub-id-type="pmid">19954808</pub-id></element-citation></ref><ref id="R56"><label>56</label><element-citation publication-type="journal"><source>Virology Journal</source><year>2012</year><volume>86</volume><fpage>12605</fpage><lpage>12615</lpage><name><surname>Garber</surname><given-names>D.A.</given-names></name><name><surname>O&#x02019;Mara</surname><given-names>L.A.</given-names></name><name><surname>Gangadhara</surname><given-names>S.</given-names></name><name><surname>McQuoid</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Zheng</surname><given-names>R.</given-names></name><name><surname>Gill</surname><given-names>K.</given-names></name><name><surname>Verma</surname><given-names>M.</given-names></name><name><surname>Yu</surname><given-names>T.</given-names></name><name><surname>Johnson</surname><given-names>B.</given-names></name></element-citation></ref><ref id="R57"><label>57</label><element-citation publication-type="journal"><source>Viruses.</source><year>2016</year><volume>8</volume><elocation-id>e139</elocation-id><name><surname>Holgado</surname><given-names>M.P.</given-names></name><name><surname>Falivene</surname><given-names>J.</given-names></name><name><surname>Maeto</surname><given-names>C.</given-names></name><name><surname>Amigo</surname><given-names>M.</given-names></name><name><surname>Pascutti</surname><given-names>M.F.</given-names></name><name><surname>Vecchione</surname><given-names>M.B.</given-names></name><name><surname>Bruttomesso</surname><given-names>A.</given-names></name><name><surname>Calamante</surname><given-names>G.</given-names></name><name><surname>del Medico-Zajac</surname><given-names>M.P.</given-names></name><name><surname>Gherardi</surname><given-names>M.M.</given-names></name><pub-id pub-id-type="pmid">27223301</pub-id></element-citation></ref><ref id="R58"><label>58</label><element-citation publication-type="journal"><source>Vaccine.</source><year>2016</year><volume>34</volume><fpage>4827</fpage><lpage>4834</lpage><name><surname>Sumner</surname><given-names>R.P.</given-names></name><name><surname>Ren</surname><given-names>H.</given-names></name><name><surname>Ferguson</surname><given-names>B.J.</given-names></name><name><surname>Smith</surname><given-names>G.L.</given-names></name><pub-id pub-id-type="pmid">27544585</pub-id></element-citation></ref></ref-list></back></article>